GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » EV-to-FCF

Can Fite Biofarma (XTAE:CANF) EV-to-FCF : (As of May. 16, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Can Fite Biofarma's Enterprise Value is ₪7.35 Mil. Can Fite Biofarma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00 Mil. Therefore, Can Fite Biofarma's EV-to-FCF for today is .

The historical rank and industry rank for Can Fite Biofarma's EV-to-FCF or its related term are showing as below:

XTAE:CANF' s EV-to-FCF Range Over the Past 10 Years
Min: -8.79   Med: -4.4   Max: -0.23
Current: -0.23

During the past 13 years, the highest EV-to-FCF of Can Fite Biofarma was -0.23. The lowest was -8.79. And the median was -4.40.

XTAE:CANF's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 7.56 vs XTAE:CANF: -0.23

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Can Fite Biofarma's stock price is ₪0.027. Can Fite Biofarma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.037. Therefore, Can Fite Biofarma's PE Ratio for today is At Loss.


Can Fite Biofarma EV-to-FCF Historical Data

The historical data trend for Can Fite Biofarma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma EV-to-FCF Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.85 -1.38 -1.36 -0.98 -0.08

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 - - - -0.08

Competitive Comparison of Can Fite Biofarma's EV-to-FCF

For the Biotechnology subindustry, Can Fite Biofarma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's EV-to-FCF falls into.



Can Fite Biofarma EV-to-FCF Calculation

Can Fite Biofarma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7.350/0
=

Can Fite Biofarma's current Enterprise Value is ₪7.35 Mil.
Can Fite Biofarma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Can Fite Biofarma  (XTAE:CANF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Can Fite Biofarma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.027/-0.037
=At Loss

Can Fite Biofarma's share price for today is ₪0.027.
Can Fite Biofarma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-0.037.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Can Fite Biofarma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (XTAE:CANF) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (XTAE:CANF) Headlines

From GuruFocus